Dear Editor,Erlotinib is an epidermal growth factor receptor (EGFR)inhibitor used in the treatment of non-small cell lung cancer.Common side effects of erlotinib include rash and diarrhea,while eyelash trichomegaly an...Dear Editor,Erlotinib is an epidermal growth factor receptor (EGFR)inhibitor used in the treatment of non-small cell lung cancer.Common side effects of erlotinib include rash and diarrhea,while eyelash trichomegaly and hair disorder are rarely reported,and corneal ulcer is less than 0.1%^([1]).展开更多
To the Editor:Acute concomitant esotropia(ACE)is an acquired esotropia with a sudden appearance and no pathologic changes on cerebral imaging.There are various treatments for ACE,including extraocular muscle surgery,b...To the Editor:Acute concomitant esotropia(ACE)is an acquired esotropia with a sudden appearance and no pathologic changes on cerebral imaging.There are various treatments for ACE,including extraocular muscle surgery,botulinum toxin A(BTA)injection,prisms,and divergence training.[1]BTA had been used in the treatment of ACE since it was approved by Food and Drug Administration(FDA,USA)in 1989.[2]Some researchers have confirmed that its effect is stable and has unique advantages in the treatment of ACE.展开更多
文摘Dear Editor,Erlotinib is an epidermal growth factor receptor (EGFR)inhibitor used in the treatment of non-small cell lung cancer.Common side effects of erlotinib include rash and diarrhea,while eyelash trichomegaly and hair disorder are rarely reported,and corneal ulcer is less than 0.1%^([1]).
基金Key Program on Basic Research Project of Universities of Henan(No.22B320016)Scientific Research Fund of National Health Commission-Henan Province Medical Science and Technology Project(No.SB201901013)
文摘To the Editor:Acute concomitant esotropia(ACE)is an acquired esotropia with a sudden appearance and no pathologic changes on cerebral imaging.There are various treatments for ACE,including extraocular muscle surgery,botulinum toxin A(BTA)injection,prisms,and divergence training.[1]BTA had been used in the treatment of ACE since it was approved by Food and Drug Administration(FDA,USA)in 1989.[2]Some researchers have confirmed that its effect is stable and has unique advantages in the treatment of ACE.
